Quarterly ResultMay 14, 2026, 08:07 AM
Lucid Diagnostics Q1 Revenue $1.3M; Processed 3,177 EsoGuard Tests
AI Summary
Lucid Diagnostics reported its first quarter 2026 financial results, with EsoGuard revenue reaching $1.3 million from 3,177 processed tests. The company posted a GAAP net loss of $23.6 million and a non-GAAP adjusted loss of $10.5 million. Lucid strengthened its balance sheet through a public offering, netting approximately $17 million, and ended the quarter with $45 million in proforma cash, extending its operational runway into 2027. The company continues to focus on securing Medicare coverage and expanding commercialization efforts for EsoGuard.
Key Highlights
- Recognized $1.3 million in EsoGuard revenue for Q1 2026.
- Processed 3,177 EsoGuard® Esophageal DNA Tests in Q1 2026.
- Reported GAAP net loss attributable to common stockholders of $23.6 million or $(0.17) per share.
- Non-GAAP adjusted loss was $10.5 million or $(0.07) per common share.
- Strengthened balance sheet with public offering, netting approximately $17 million in proceeds.
- Ended Q1 2026 with $45 million in proforma cash, extending runway into 2027.
- Cash and cash equivalents were $27.9 million as of March 31, 2026.
- Anticipates Medicare coverage and other key reimbursement milestones.
Price Impact
More from LUCD